Medigene spins out AAV tech to a new biotech upstart in Sweden
Germany’s Medigene AG is getting a new biotech startup going, out-licensing its AAV-like particle tech to the newly minted Swedish biotech company 2A Pharma AB, located in Malmö, Sweden.
Medigene says that it was working on AAV particle tech before devoting itself to T cells and immunotherapy. And now 2A Pharma plans to use it to develop new vaccines, for cancer as well as infectious diseases. And the upstart says it’s raised enough cash to take the biotech up to the clinic, though it did not spell out the details on that score.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.